Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PHAT | Common Stock | Sale | -$30M | -3.7M | -49.65% | $8.10 | 3.76M | Jan 24, 2024 | Direct |
Takeda Pharmaceutical Co Ltd is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.